Lobe Sciences Secures European Patent for Sickle Cell Disease Treatment

Lobe Sciences Ltd. has announced the validation of its European Unitary Patent EP4117446, securing protection in 17 EU member states for a composition designed to manage Sickle Cell Disease (SCD). This patent covers Altemia®, a medical food formula addressing long-chain fatty acid deficiencies prevalent in SCD patients.

The composition leverages Docosahexaenoic Acid (DHA) and natural emulsifiers, enhancing treatment efficacy by restoring red blood cell membrane integrity. With protection across key markets, including Germany, France, and Italy, Lobe aims to expand its reach in Europe.

This milestone supports Lobe's global expansion strategy for Altemia® and strengthens its intellectual property portfolio. According to CEO Dr. Fred D. Sancilio, this patent solidifies the company's efforts to innovate SCD treatment options.